IP11 - AEGEAN
Research type
Research Study
Full title
Understanding the Abscopal effect in Prostate Cancer – Primary and Metastatic Tumour Crosstalk
IRAS ID
342331
Contact name
Taimur Shah
Contact email
Sponsor organisation
Imperial College London
Clinicaltrials.gov Identifier
ECMCQQR-2022/100015, NIHR/CRUK ECMC
Duration of Study in the UK
3 years, 0 months, 30 days
Research summary
Many men present with or rapidly progress to cancer that has spread, which then develops lethal therapy-resistant metastases. Our study will investigate how treatment to the primary tumour impacts secondary lesions – this “abscopal effect” is established by comparing primary cancer treated with surgery or radiotherapy, against standard-of-care therapy. We will, uniquely, investigate effects of these treatments on the genome, transcriptome, phenotype and therapy response in primary and different metastatic sites. Our findings will enable better tailoring of therapies to men with metastatic disease, to slow or even prevent transition to therapy resistance. It will ultimately also catalyse studies elucidating treatment resistance and developing novel treatments for advanced, therapy-resistant disease.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
24/PR/1005
Date of REC Opinion
26 Sep 2024
REC opinion
Further Information Favourable Opinion